Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

May 7, 2026 4:20 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm:EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including:American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)Philadelphia, PA, USABritish Thyroid Association (BTA)London, UKChild Neurology Society (CNS)Montreal, CanadaEuropean Society for Paediatric Endocrinology (ESPE)Marseille,...

Read more

Vicore Pharma Elects Peter Guenter to its Board of Directors

May 7, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Peter Guenter has been elected as a new member of the Board of Directors.Peter Guenter brings nearly four decades of leadership experience in the global pharmaceutical industry, including roles as Chief Executive Officer at two major...

Read more

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York

May 6, 2026 8:00 PM

Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital...

Read more

Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)

May 6, 2026 10:45 AM

Today on 6 May 2026, the Annual General Meeting (the "AGM") of Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company")(STO:VICO) was held, whereby the shareholders passed the following resolutions.Adoption of the income statement and the balance sheetThe AGM resolved to adopt the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet for the financial year 2025.Allocation of...

Read more

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

May 6, 2026 6:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an...

Read more

Bulletin from The Annual General Meeting in Alligator Bioscience AB on 6 May 2026

May 6, 2026 5:35 AM

Alligator Bioscience (STO:ATORX)The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.Today, on 6 May 2026, the annual general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and distribution of the company's resultThe annual general meeting resolved to adopt...

Read more

Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service

May 6, 2026 2:20 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that it has terminated the liquidity provision agreement with Lago Kapital Oy, with the termination taking effect on 5 June 2026.The Company estimates that the current liquidity of the shares in the Company is sufficient without additional liquidity providers.For more information, please contact:IR...

Read more

Interim Report January - March 2026

May 6, 2026 2:20 AM

Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the first quarter 2026."For the more than 300,000 people diagnosed with idiopathic pulmonary fibrosis in the United States and Europe alone, time is the scarcest resource. IPF is progressive, relentless, and still without a cure. It is this reality that drives...

Read more

Biovica International AB Announces Change in Executive Management

May 5, 2026 3:45 PM

Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) - Biovica International AB ("Biovica") today announces that the company's Chief Financial Officer, Anders Morén, has resigned on his own initiative to pursue independent business activities.Anders Morén will remain in his role during his agreed six-month notice period to ensure an orderly handover.The Company has initiated the recruitment process to appoint a successor and will inform...

Read more

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

May 5, 2026 1:05 PM

Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's execution of an $815 million definitive exclusive license agreement with BCM Europe AG (BCME) for the global development, commercialization, and out-licensing of VXM01 - a Phase-2b/3 ready oral immunotherapy for glioblastoma multiforme (GBM) and...

Read more

GeneTex Formalizes Collaboration with the Human Protein Atlas

May 5, 2026 10:00 AM

GeneTex, a multinational recombinant antibody manufacturer, is excited to announce the formalization of a collaborative relationship with the renowned Human Protein Atlas (HPA), a peerless, open-access multi-laboratory organization whose primary goal is to establish a comprehensive map of the human proteome using an integrated omics approach involving antibody-based proteomics and transcriptomics.The HPA's importance to the biomedical and...

Read more

AI Maverick Intel Highlights Accelerating Commercial Traction at HEAL Access as It Advances Proposed Acquisition

May 5, 2026 7:00 AM

AI Maverick Intel, Inc. ("AIMV" or the "Company") is providing an update on the continued commercial progress of HEAL Access Canada Inc. (together with its subsidiaries, "HEAL Access" or "HAC"), in connection with AIMV's previously announced non-binding letter of intent ("LOI") to acquire 100% of HAC.Based on information provided to the Company by HEAL Access, the platform has reached a level of commercial deployment that AIMV believes reflects...

Read more

Longwood Healthcare Leaders to Host MIT CEO, Off-the-Record Networking and Discussion Forum, Convening Life Science Thought Leaders at MIT Koch Institute

May 5, 2026 7:00 AM

Longwood Healthcare Leaders convenes top biopharmaceutical leaders for two days of off-the-record discussion, June 15-16, 2026, at MIT CEO, co-hosted with Sally Kornbluth (President, MIT), Nobelist Phil Sharp (co-founder, Biogen/Alnylam), Bob Langer (co-founder, Moderna/Momenta), Matthew Vander Heiden (Director, Koch Institute), and Christoph Westphal (GP, Longwood Fund; Founder/CEO, Alnylam/Momenta), held at MIT's Koch Institute in Kendall...

Read more

Faron Pharmaceuticals Ltd: Holding(S) In Company

May 5, 2026 3:50 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANYTR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals OY1b. Please indicate if the issuer is a non-UK...

Read more

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.

May 5, 2026 2:20 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office (USPTO) granted Patent No. US 12611383B1 for the Company's patent application No. 19/261,360 entitled "Pharmaceutical Compositions for Treating MCT8 Deficiency".The newly granted patent provides protection for a novel composition, which contains tiratricol as the active ingredient, designed to...

Read more

Alligator Bioscience AB Reports Financial Results for The Period 1 January – 31 March 2026 and Provides a Business Update

May 5, 2026 2:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the first quarter of 2026 and provided a business update."During the first quarter of 2026, we continued to execute against our strategic priorities in a challenging biotech environment. We strengthened the clinical and translational foundation of mitazalimab...

Read more

Faron Pharmaceuticals Ltd: Directorate Appointment

May 5, 2026 2:20 AM

Faron Pharmaceuticals Ltd. ("Faron") (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies, is pleased to announce the appointment of Dr. George Stanley Golumbeski as a Non-executive Director of the Company with immediate effect.Dr. Golumbeski currently focuses on supporting the growth of emerging companies as a partner at DROIA Ventures, a specialized biotech investment firm. He...

Read more

Faron Pharmaceuticals Ltd: Results of the Annual General Meeting

May 4, 2026 7:10 AM

The annual general meeting ("AGM") of Faron Pharmaceuticals Ltd (LSE:FARN)(First North:FARON) took place in Turku, Finland, today 4 May 2026. Thirty-nine shareholders representing 46,850,172 shares and votes were represented in the meeting. The AGM approved all the proposals of the Board of Directors ("Board") and the Shareholder's Nomination Board, set out in the notice of the AGM published on 10 April 2026.Decisions of the AGMThe AGM adopted...

Read more

FOMAT Becomes Largest Embedded Research Organization in the U.S. with Acquisition of Topography Health's Research Sites

May 1, 2026 10:05 AM

FOMAT Medical Research, an Embedded Research Organization (ERO) focused on expanding access to clinical trials, today announced it has acquired Topography Health's research site business unit, a U.S.-based clinical research enablement company that brings trials into community-based physician practices. Financial terms of the deal were not disclosed.The acquisition expands FOMAT's network to more than 35 sites across six states - Maryland,...

Read more

Cloud-Clone Supports Groundbreaking Cell Metabolism Study: Gut Microbial Metabolite Promotes Fat Thermogenesis via Immune System

April 30, 2026 12:00 PM

A groundbreaking study published in the prestigious journal Cell Metabolism (IF=30.9) has revealed a novel signaling axis connecting gut microbiota, immune cells, and progenitor adipocytes, offering a fresh target for metabolic disease intervention. The study demonstrates that cold exposure significantly increases the levels of Prevotella copri and its metabolic product, 3-phenylpropionic acid (3-PPA), which activates communication between...

Read more